CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES >
Progress researches on Budd-Chiari syndrome and portal hypertension caused by hepatic alveolar echinococcosis
Received date: 2025-06-30
Revised date: 2025-09-08
Online published: 2026-02-10
Supported by
National Natural Science Foundation of China(82260412);2024 Kunlun Talents High-end Innovation and Entrepreneurship Talents of Qinghai Province (Qingrencai Zi [2025] 5);Qinghai Provincial People’s Hospital-Soochow University Joint Training Program of High-Level Health Personnel Project(2025-qhsrmyysd-01);Guiding Project of Qinghai Provincial Health Commission(2020-wjzdx-27)
Hepatic alveolar echinococcosis is a zoonotic parasitic disease that is known as the parasite cancer. Lesions of hepatic alveolar echinococcosis tend to grow along the intrahepatic blood vessels, and large lesions may directly invade or compress adjacent portal veins, hepatic vein, trunk, and the post-hepatic segment of the inferior vena cavar esulting in that the majority of patients with end-stage hepatic alveolar echinococcosis are complicated with cardiac cirrhosis, Budd-Chiari syndrome, or portal hypertension at varying degrees. This not only increases the difficulty in diagnosis and treatment for hepatic alveolar echinococcosis, but also raises the cost of disease treatment. Currently, the pathogenesis of hepatic alveolar echinococcosis induced portal hypertension, Budd-Chiari syndrome, and cardiac cirrhosis is not fully understood, and there are still controversies regarding diagnosis and treatment of these complications. This article provides a brief overview of the clinical symptoms induced by hepatic alveolar echinococcosis, including cardiac cirrhosis, Budd-Chiari syndrome, and portal hypertension.
A Jide , CHAI Jinping , JING Qindong , PAN Hongshuai . Progress researches on Budd-Chiari syndrome and portal hypertension caused by hepatic alveolar echinococcosis[J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2026 , 44(1) : 118 -123 . DOI: 10.12140/j.issn.1000-7423.2026.01.017
| [1] | Bresson-Hadni S, Spahr L, Chappuis F. Hepatic alveolar echinococcosis[J]. Semin Liver Dis, 2021, 41(3): 393-408. |
| [2] | Wang SB, Ma YB, Wang WS, et al. Status and prospect of novel treatment options toward alveolar and cystic echinococcosis[J]. Acta Trop, 2022, 226: 106252. |
| [3] | Wen H, Vuitton L, Tuxun T, et al. Echinococcosis: advances in the 21st Century[J]. Clin Microbiol Rev, 2019, 32(2): e00075-18. |
| [4] | Deplazes P, Rinaldi L, Alvarez Rojas CA, et al. Global distribution of alveolar and cystic echinococcosis[J]. Adv Parasitol, 2017, 95: 315-493. |
| [5] | 杜云峰, 姜慧娇, 刘程豪, 等. 舒尼替尼与阿苯达唑联合用药对泡状棘球蚴治疗效果的实验研究[J]. 石河子大学学报(自然科学版), 2023, 41(5): 599-607. |
| Du YF, Jiang HQ, Liu CH, et al. Sunitinib in combination with albendazole for the treatment of alveolar echinococcosis[J]. J Shihezi Univ Nat Sci, 2023, 41(5): 599-607. (in Chinese) | |
| [6] | 黄燕, 喻文杰, 尚婧晔, 等. 阿苯达唑和吡喹酮交替联合用药治疗藏族牧民棘球蚴病的效果观察[J]. 中国寄生虫学与寄生虫病杂志, 2021, 39(2): 171-177. |
| Huang Y, Yu WJ, Shang JY, et al. Efficacy of alternative and combined use of albendazole plus praziquantel in the treatment of echinococcosis for Tibetan herdsmen[J]. Chin J Parasitol Parasit Dis, 2021, 39(2): 171-177. (in Chinese) | |
| [7] | 中国医师协会外科医师分会包虫病外科专业委员会. 肝两型包虫病诊断与治疗专家共识(2019版)[J]. 中华消化外科杂志, 2019, 18(8): 711-721. |
| The Committee of Echinococcosis Surgery, Chinese Society of Surgical Physicians, Chinese Medical Doctor Association. Expert consensus on diagnosis and treatment of hepatic cystic and alveolar echinococcosis (2019 edition)[J]. Chin J Dig Surg, 2019, 18(8): 711-721. (in Chinese) | |
| [8] | Craig PS, Giraudoux P, Wang ZH, et al. Echinococcosis transmission on the Tibetan Plateau[J]. Adv Parasitol, 2019, 104: 165-246. |
| [9] | 四川省包虫病临床医学研究中心, 四川省医师协会包虫病专业委员会. 泡型肝包虫病诊疗专家共识(2020版)[J]. 中国普外基础与临床杂志, 2020, 27(1): 13-17. |
| Sichuan Clinical Medicine Research Center for Echinococcosis, Echinococcosis Professional Committee of Sichuan Medical Association. Expert consensus on diagnosis and treatment of alveolar echinococcosis (2020 edition)[J]. Chin J Bases Clin Gen Surg, 2020, 27(1): 13-17. (in Chinese) | |
| [10] | Kantarci M, Bayraktutan U, Karabulut N, et al. Alveolar echinococcosis: spectrum of findings at cross-sectional imaging[J]. Radiographics, 2012, 32(7): 2053-2070. |
| [11] | Brunetti E, Kern P, Vuitton DA. Expert consensus for the diagnosis and treatment of cystic andalveolar echinococcosis in humans[J]. Acta Trop, 2010, 114(1): 1-16. |
| [12] | 王茂林, 邵英梅. 肝包虫病合并门静脉海绵样变性的研究进展[J]. 临床肝胆病杂志, 2021, 37(4): 965-968. |
| Wang ML, Shao YM. Research advances in hepatic echinococcosis with cavernous transformation of the portal vein[J]. J Clin Hepatol, 2021, 37(4): 965-968. (in Chinese) | |
| [13] | Zawistowski M, Nowaczyk J, Jakubczyk M, et al. Outcomes of ex vivo liver resection and autotransplantation: a systematic review and meta-analysis[J]. Surgery, 2020, 168(4): 631-642. |
| [14] | 李震, 丁鹏绪, 汪忠镐. 布-加综合征的规范化治疗[J]. 中国血管外科杂志(电子版), 2013, 5(3): 155-157. |
| Li Z, Ding PX, Wang ZG. Standardized treatment of Budd-Chiari syndrome[J]. Chin J Vasc Surg Electron Version, 2013, 5(3): 155-157. (in Chinese) | |
| [15] | Ran B, Jiang TM, Yasen A, et al. Left trisectionectomy and supra-hepatic caval reconstruction with vascular prosthesis for chronic Budd-Chiari syndrome caused by hepatic alveolar echinococcosis[J]. Chin Med J (Engl). 2019, 132(23): 2886-2888. |
| [16] | Alghofaily KA, Saeedan MB, Aljohani IM, et al. Hepatic hydatid disease complications: review of imaging findings and clinical implications[J]. Abdom Radiol, 2017, 42(1): 199-210. |
| [17] | 王雯, 李玮, 齐梦剑, 等. 肝细胞癌合并门静脉癌栓形成机制的研究进展[J]. 中华肝胆外科杂志, 2023, 29(4): 305-308. |
| Wang W, Li W, Qi MJ, et al. Research progress on the formation mechanism of hepatocellular carcinoma with portal vein tumor thrombus[J]. Chin J Hepatobiliary Surg, 2023, 29(4): 305-308. (in Chinese) | |
| [18] | 尹先敏, 种世桂, 陈根, 等. 巨噬细胞调控多房棘球蚴病所致肝纤维化研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2024, 42(6): 790-795, 801. |
| Yin XM, Chong SG, Chen G, et al. Research progress of macrophage regulation of liver fibrosis induced by alveolar echinococcosis[J]. Chin J Parasitol Parasit Dis, 2024, 42(6): 790-795, 801. (in Chinese) | |
| [19] | 谢芝芝, 黄艳, 余新炳. 寄生虫感染致肝纤维化机制的研究进展[J]. 热带医学杂志, 2013, 13(9): 1161-1165. |
| Xie ZZ, Huang Y, Yu XB. Research progress on the mechanism of liver fibrosis caused by parasitic infection[J]. J Trop Med, 2013, 13(9): 1161-1165. (in Chinese) | |
| [20] | Valla DC. Budd-Chiari syndrome/hepatic venous outflow tract obstruction[J]. Hepatol Int, 2018, 12(Suppl 1): 168-180. |
| [21] | Collado Aliaga J, Romero-Alegría á, Alonso-Sardón M, et al. Portal hypertension as a complication of cystic echinococcosis: a 20-Year cohort analysis[J]. Am J Trop Med Hyg, 2021, 105(3): 692-697. |
| [22] | Zhang Y, Yang C, Yang H, et al. Comment on “The value of hepatic vein stent placement as a bridge therapy on treating hepatic alveolar echinococcosis presenting with Budd-Chiari syndrome”[J]. Ann Surg, 2021, 274(6): e923-e924. |
| [23] | Yang C, Yang HJ, Deng SP, et al. Current status of ex-vivo liver resection and autologous liver transplantation for end-stage hepatic alveolar echinococcosis[J]. Ann Palliat Med, 2020, 9(4): 2271-2278. |
| [24] | Qiu YW, Huang B, Yang XW, et al. Evaluating the benefits and risks of ex vivo liver resection and autotransplantation in treating hepatic end-stage alveolar echinococcosis[J]. Clin Infect Dis, 2022, 75(8): 1289-1296. |
| [25] | Shen S, Kong JJ, Qiu YW, et al. Ex vivo liver resection and autotransplantation versus allotransplantation for end-stage hepatic alveolar echinococcosis[J]. Int J Infect Dis, 2019, 79: 87-93. |
| [26] | 阿吉德, 柴金萍, 赵顺云, 等. 保留肝后下腔静脉的离体肝切除、 自体肝移植术在治疗终末期肝泡型包虫病中的临床应用[J]. 中华肝胆外科杂志, 2019, 25(11): 860-862. |
| A JD, Chai JP, Zhao SY, et al. Clinical application of isolated hepatectomy with preservation of retrohepatic inferior vena cava and autologous liver transplantation in treating end-stage alveolar hepatic hydatid disease[J]. Chin J Hepatobiliary Surg, 2019, 25(11): 860-862. (in Chinese) | |
| [27] | Zanetto A, Pellone M, Senzolo M. Milestones in the discovery of Budd-Chiari syndrome[J]. Liver Int, 2019, 39(7): 1180-1185. |
| [28] | Mukund A, Sarin SK. Budd-Chiari syndrome: A focussed and collaborative approach[J]. Hepatol Int, 2018, 12(6): 483-486. |
| [29] | Sharma A, Keshava SN, Eapen A, et al. An update on the management of Budd-Chiari syndrome[J]. Dig Dis Sci, 2021 66(6): 1780-1790. |
| [30] | 徐凯, 王海久, 张丽, 等. 多房棘球蚴对宿主肝细胞损害机制的研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2021, 39(2): 256-260. |
| Xu K, Wang HJ, Zhang L, et al. Research progress on the mechanisms underlying the impairment of host hepatocytes by Echinococcus multilocularis[J]. Chin J Parasitol Parasit Dis, 2021, 39(2): 256-260. (in Chinese) | |
| [31] | 王苗苗, 安秀青, 周鸿乾, 等. 肝多房棘球蚴病导致肝硬化的研究进展[J]. 中国人兽共患病学报, 2023, 39(11): 1130-1135. |
| Wang MM, An XQ, Zhou HQ, et al. Research progress in hepaticalveolar echinococcosis leading to cirrhosis[J]. Chin J Zoonoses, 2023, 39(11): 1130-1135. (in Chinese) | |
| [32] | Liu TL, Li H, Li YP, et al. Integrative analysis of RNA expression and regulatory networks in mice liver infected by Echinococcus multilocularis[J]. Front Cell Dev Biol, 2022, 10: 798551. |
| [33] | Niu FQ, Chong SG, Qin MQ, et al. Mechanism of fibrosis induced by Echinococcus spp.[J]. Diseases, 2019, 7(3): 51. |
| [34] | Higashi T, Friedman SL, Hoshida Y. Hepatic stellate cells as key target in liver fibrosis[J]. Adv Drug Deliv Rev, 2017, 121: 27-42. |
| [35] | 玉苏甫卡迪尔·麦麦提尼加提, 艾麦提·牙森, 张瑞青, 等. 转化生长因子β1在泡状棘球蚴感染所致肝纤维化中的作用机制[J]. 医学研究生学报, 2020, 33(2): 127-132. |
| Yusufukadier MMTNJT, Aimaiti YS, Zhang RQ, et al. Role of TGF-β1 in hepatic fibrosis induced by Echinococcus multilocular infection[J]. J Med Postgrad, 2020, 33(2): 127-132. (in Chinese) | |
| [36] | 岳彩飞, 洪汝涛. 褪黑素对PDGF诱导肝纤维化的影响及其可能机制[J]. 重庆医科大学学报, 2021, 46(12): 1421-1424. |
| Yue CF, Hong RT. Effect of melatonin on liver fibrosis induced by platelet-derived growth factor and its possible mechanism[J]. J Chongqing Med Univ, 2021, 46(12): 1421-1424. (in Chinese) | |
| [37] | Sufle?el RT, Melincovici CS, Gheban BA, et al. Hepatic stellate cells-from past till present: morphology, human markers, human cell lines, behavior in normal and liver pathology[J]. Rom J Morphol Embryol, 2020, 61(3): 615-642. |
| [38] | Thabut D, Routray C, Lomberk G, et al. Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis[J]. Hepatology, 2011, 54(2): 573-585. |
| [39] | Bosch J, Groszmann RJ, Shah VH. Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments[J]. J Hepatol, 2015, 62(1 Suppl): S121-S130. |
| [40] | DeLeve LD. Liver sinusoidal endothelial cells in hepatic fibrosis[J]. Hepatology, 2015, 61(5): 1740-1746. |
| [41] | Mirzavand S, Rafiei A, Teimoori A, et al. Gene expression in human liver fibrosis associated with Echinococcus granulosus sensu lato[J]. Parasitol Res, 2020, 119(7): 2177-2187. |
| [42] | 闵宏悦, 田凤鸣, 张靖仪, 等. MCP-1介导单核细胞浸润在泡型包虫病肝纤维化中的作用[J]. 中国病原生物学杂志, 2023, 18(4): 400-405, 410. |
| Min HY, Tian FM, Zhang JY, et al. Role of monocyte chemotactic protein 1-mediated monocyte infiltration in liver fibrosis of alveolar echinococcosis[J]. J Parasit Biol, 2023, 18(4): 400-405, 410. (in Chinese) | |
| [43] | 曹涛, 杨育文, 杨效, 等. TGF-β1 p38MAPK及BMP-7蛋白在肝多房棘球蚴病患者肝组织中的表达及意义[J]. 中国血吸虫病防治杂志, 2021, 33(4): 353-358. |
| Cao T, Yang YW, Yang X, et al. Expression and significance of TGF-β1, p38MAPK and BMP-7 protein in liver specimens of patients with alveolar hepatic echinococcosis[J]. Chin J Schisto Control, 2021, 33(4): 353-358. (in Chinese) | |
| [44] | Schumacher JD, Guo GL. Regulation of hepatic stellate cells and fibrogenesis by fibroblast growth factors[J]. BioMed Res Int, 2016, 2016: 8323747. |
| [45] | Iwakiri Y. Nitric oxide in liver fibrosis: the role of inducible nitric oxide synthase[J]. Clin Mol Hepatol, 2015, 21(4): 319-325. |
| [46] | Zhang MJ, Zhang S. T cells in fibrosis and fibrotic diseases[J]. Front Immunol, 2020, 11: 1142. |
| [47] | 马福财, 杨德武, 王铮, 等. miR-106b-25基因簇在肝泡型包虫病肝组织中的表达及意义[J]. 中国人兽共患病学报, 2022, 38(7): 631-637. |
| Ma FC, Yang DW, Wang Z, et al. Expression and clinical significance of the miR-106b-25 gene cluster in liver tissues of patients with alveolar echinococcosis[J]. Chin J Zoonoses, 2022, 38(7): 631-637. (in Chinese) | |
| [48] | Choi JS, Jeong IS, Han JH, et al. IL-10-secreting human MSCs generated by TALEN gene editing ameliorate liver fibrosis through enhanced anti-fibrotic activity[J]. Biomater Sci, 2019, 7(3): 1078-1087. |
| [49] | Tian FM, Jiang T, Qi XW, et al. Role of cytokines on the progression of liver fibrosis in mice infected with Echinococcus multilocularis[J]. Infect Drug Resist, 2021, 14: 5651-5660. |
| [50] | Chen K, Kolls JK. Interluekin-17A (IL17A)[J]. Gene, 2017, 614: 8-14. |
| [51] | 鄂维建, 芦永良, 祁秉民, 等. 血清巨噬细胞极化相关因子与多房棘球蚴病肝纤维化的相关性分析[J]. 临床肝胆病杂志, 2021, 37(12): 2813-2818. |
| E WJ, Lu YL, Qi BM, et al. Association between serum macrophage polarization-related factors and liver fibrosis in echinococcosis multilocularis[J]. J Clin Hepatol, 2021, 37(12): 2813-2818. (in Chinese) |
/
| 〈 |
|
〉 |